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Abstract: 
 
As part of our ongoing investigation of filamentous fungi for anticancer leads, an active fungal 
extract was identified from the Mycosynthetix library (MSX 55526; from the Order Sordariales). 
Bioactivity-directed fractionation yielded the known ergosterol peroxide (2) and 5α,8α-
epidioxyergosta-6,9(11),22-trien-3β-ol (3), and a new benzoate trimer, termed thielavin B methyl 
ester (1). The structure elucidation of 1 was facilitated by the use of HRMS coupled to an APPI 
(atmospheric pressure photoionization) source. Compound 1 proved to be moderately active 
against a panel of three cancer cell lines. 
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Article: 
 
The pursuit of drug leads from fungi has yielded thousands of interesting compounds, many of 
which have become important drugs. Penicillin and lovastatin may be the most well-known 
examples from the 20th century,1 but even in the last 12 months, the U.S. FDA approved a new 
treatment for multiple sclerosis, fingolimod (trade name, Gilenya), which was optimized via 
medicinal chemistry from the fungal secondary metabolite, myriocin.2 Hence, fungi have, and 
continue to be, a reservoir for drug discovery. 
 
Through the ongoing exploration of extracts of filamentous fungi for anticancer drug leads,3the 
crude 1:1 CHCl3/MeOH extract of fungus MSX 555264 displayed promising cytotoxicity (i.e., 
>97% inhibition of the growth of H460 cells when tested at 20 μg/mL). This extract was 
partitioned with 3:3:4 MeOH/CH3CN/hexanes, and the residue from the bottom layer (1.14 g) 
was then fractionated by flash silica-gel chromatography. The material eluting at ∼2–3% MeOH 
in CHCl3 was active (>95% inhibition of H460 cell growth when tested at 2 μg/mL). Preparative 
scale RP-HPLC (gradient of CH3CN in H2O on C18) was utilized to isolate all compounds of 
interest in >95% purity, as evaluated by UPLC-ELSD.5Compounds 2 and 3 were known 
compounds, ergosterol peroxide and 5α,8α-epidioxyergosta-6,9(11),22-trien-3β-ol, respectively; 
their NMR data were in good agreement with the literature.6, 7 Compound 1 (1.1 mg), however, 
was a new benzoate trimer (Fig. 1), the structure elucidation of which was facilitated greatly by 
the use of high resolution mass spectrometery (HRMS) with an atmospheric pressure 
photoionization (APPI) source.8 
 
 
Figure 1. Structure of Thielavin B methyl ester (1). 
 
The HRMS of compound 1 showed [M+H]+ at 581.2378, corresponding to a molecular formula 
of C32H36O10 (calcd 581.2387 for [M+H]+), corresponding to an index of hydrogen deficiency of 
15 and indicative of a high degree of unsaturation. The 1H NMR spectrum of 1was somewhat 
atypical (see Supplementary data), particularly for a natural product of m.w. >500 amu, as it 
showed all singlets; eight singlets were consistent with aromatic methyl groups, three singlets 
were consistent with methoxy groups, a one-proton singlet that was consistent with an aromatic 
proton, and a one-proton singlet that was consistent with an intramolecular hydrogen-bonded 
phenol. 
 
A search of the formula in the Dictionary of Natural Products9 returned ten hits, seven of which 
were compounds of fungal origin. Two of the hits, thielavin C10 and Antibiotic PS-990,11 had 
spectroscopic data that were similar, but not entirely consistent, with compound 1. Specifically, 
both thielavin C and PS-990 had nine aromatic methyl groups, two methoxy groups, and no 
aromatic proton. The UV spectrum of 1 from the diode-array detector of the HPLC showed a 
maximum at 276 nm and a shoulder at approximately 310 nm, and of the two known compounds, 
these data more closely matched those of thielavin C.10 
 
 
Figure 2. HMBC correlations of Thielavin B methyl ester (1). 
 
From the HMBC spectrum (Fig. 2), it was apparent that the compound was indeed closely 
related to thielavin C, containing three benzoates linked by two p-phenoxy groups. The key 
differences between thielavin C and 1 were that one of the rings in 1 was not fully substituted, 
and compound 1 terminated at the carboxyl end with a methyl ester instead of a carboxylic acid. 
HMBC data further revealed that two of the benzoate rings had identical substitution patterns (2-
methoxy-4-phenoxy-3,5,6-trimethyl), while the substitution pattern for the third benzoate was 
2,4-diphenoxy-3,6-dimethyl. The question that could not be answered by HMBC was the 
sequence of the three benzoates. 
 
Two methods were used to elucidate the sequence of the benzoate rings. The first was NOESY 
spectroscopy (see Supplementary data for spectrum). The NOESY spectrum showed both intra-
ring correlations (Fig. 3, dashed lines), and inter-ring correlations (Fig. 3, solid lines), which 
proved that the methyl ester was part of one of the hexa-substituted rings, while the sequence 
terminated at the phenolic end with the penta-substituted ring. 
 
 
Figure 3. NOESY correlations of Thielavin B methyl ester (1). 
 
The second method, which confirmed the ring sequence, was HRMS coupled to an APPI source 
(Fig. 4, see Supplementary data for spectrum). APPI is an ionization technique that utilizes UV 
photons to generate the quasi-molecular ion (i.e., [M+H]+) through charge transfer reactions 
between the solvent and the analyte of interest.12 APPI has been demonstrated to ionize 
compounds with a high degree of unsaturation preferentially, as was observed with 1.13 The use 
of APPI is routine in the analysis of crude oil,14, 15, 16, 17, 18 whereas, in the analysis of natural 
products, APPI has been used largely for the measurement or identification of targeted 
compounds, such as aflatoxins,19 pesticide residues,20 and naphthalenes.21 Thus, to the best of our 
knowledge, this represents the first example of its utility in the de novo structure elucidation of 
bioactive secondary metabolites, particularly when coupled to HRMS. In positive mode, in-
source fragmentation occurred at the ester bonds (Fig. 4), revealing all of the possible fragments 
and confirming the sequence as deduced by NOESY. These data indicated compound 1 was the 
methyl ester of thielavin B, and hence was ascribed the trivial name thielavin B methyl ester. 
 
 
Figure 4. APPI-HRMS in-source fragmentation of 1. 
 
Compound 1 was assayed against the MCF-7 (human breast carcinoma), H460 (human non-
small cell lung carcinoma), and SF268 (human astrocytoma) cell lines exactly as described 
previously.22 The IC50 values for 1 were 7.3, 6.6, and 8.1 μM, respectively. In our hands, activity 
of this order of magnitude was considered ‘moderate’, since positive controls (i.e., camptothecin) 
have IC50 values in the sub-μM range.22 
 
In conclusion, a new congener (1) in the thielavin series was isolated via bioactivity-directed 
purification. Compound 1 was shown by a combination of 2D NMR and APPI-HRMS to be the 
methyl ester of thielavin B. APPI-HRMS was demonstrated to be an effective method for 
elucidating the sequence of benzoate rings for this class of compounds, and the MS conclusions 
were confirmed by 2D NOESY spectroscopy. Thielavin B methyl ester (1) exhibited moderate 
cytotoxicity. Other members of this class of tribenzoates have shown inhibition of prostaglandin 
biosynthesis10, 23 and inhibition of phospholipase A2,24 both implicated in inflammation. The 
thielavins have also shown inhibitory activity against glucose-6-phosphatase, a possible target 
for anti-diabetic drug leads.25 Antibiotic PS-990 was shown to be a cyclic nucleotide 
phosphodiesterase inhibitor, a potential target for treatment of neurodegenerative conditions.11 
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1H and 13C NMR Spectra of Thielavin B methyl ester (1), 500 MHz, CDCl3 
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NOESY Spectrum of Thielavin B methyl ester (1) 
 
HO CH3
OH
O
O
H3C
CH3
CH3
OCH3
O
O
H3C
OCH3
CH3
CH3
OCH3
O
H3C
H
A 
B 
C 
NOESY Spectrum of Thielavin B methyl ester (1) 
 
HO CH3
OH
O
O
H3C
CH3
CH3
OCH3
O
O
H3C
OCH3
CH3
CH3
OCH3
O
H3C
H
A 
B 
C 
Table S1. 1H NMR (500 MHz) and 13C NMR (125 MHz) data for Thielavin B methyl ester (1) 
in CDCl3 
Position Thielavin B methyl ester 
 
δC δH, mult 
1-carbonyl 169.1 --- 
1 127.7 --- 
1-OCH3 ester 52.5 3.94, s 
2 153.8 --- 
2-OCH3 62.3 3.80, s 
3 122.3 --- 
3-CH3 10.5 2.26, s 
4 149.6 --- 
5 125.9 --- 
5-CH3 13.2 2.23, s 
6 132.8 --- 
6-CH3 17.1 2.22, s 
1ʹ-carbonyl 166.3 --- 
1ʹ 126.8 --- 
2ʹ 154.6 --- 
2ʹ-OCH3 62.5 3.84, s 
3ʹ 122.4 --- 
3ʹ-CH3 10.5 2.17, s 
4ʹ  149.7 --- 
5ʹ 126.0 --- 
5ʹ-CH3 13.4 2.13, s 
6ʹ 133.8 --- 
6ʹ-CH3 17.5 2.41 
1ʹʹ-carbonyl 170.3 --- 
2ʹʹ 164.6 --- 
2ʹʹ-OH --- 11.85, s 
3ʹʹ 109.2 --- 
3ʹʹ-CH3 7.8 2.14, s 
4ʹʹ 160.0 --- 
5ʹʹ 111.5 6.34, s 
6ʹʹ 141.0 --- 
6ʹʹ-CH3 25.1 2.65, s 
 
 
 
 
 
APPI-HRMS of Thielavin B methyl ester (1) 
 
 
01007-148-1 posion APPI sum 200 run 2 FT #1-200 RT: 0.01-2.84 AV: 200 NL: 3.43E9
T: FTMS + p APCI corona Full ms [150.00-1000.00]
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